BeOne Medicines Ltd. ONC
Deals with insiders in the proxy filed Apr 28, 2026
Proxy, Item 404Deals between ONC and its directors, executives, owners of more than 5% or their families: a relative on the payroll, a plane the company charters from its CEO, a director's company that buys from it. SEC rules (Item 404) make the company list every such deal over $120,000 in its proxy statement.
New this year
Compared with Apr 7, 2025
Paragraphs about a deal, a person or a relative with nothing like them in the proxy filed Apr 7, 2025.
Share Purchase Agreement“In connection with the Collaboration Agreement, pursuant to a Share Purchase Agreement dated October 31, 2019, by and between the Company and Amgen (as amended, the “Share Purchase Agreement”), we issued 206,635,013 ordinary shares in the form of 15,895,001 ADSs on January 2, 2020, representing approximately 20.5% of our then outstanding shares to Amgen, for an aggregate purchase price of US$2.78 billion, or US$13.45 per ordinary share, or US$174.85 per ADS.”
Read it in the proxyopen_in_new
Certain Relationships and Related-Party Transactions“On January 30, 2023, BeOne Medicines Ltd. and Amgen entered into an Amendment No. 3 to the Share Purchase Agreement, pursuant to which Amgen elected to relinquish its right to appoint a designated director to the Company’s Board of Directors on account of the Company’s global growth. Mr. Anthony C. Hooper, who was Amgen’s director designee, was most recently re-elected by shareholders in 2025.”
Read it in the proxyopen_in_new
Sublease Agreement“On January 17, 2025, our wholly-owned subsidiary, BeOne Medicines US Holdings, LLC entered into a sublease agreement with ChemoCentryx, Inc., an affiliate of Amgen, to lease property in San Carlos, California, for the establishment of additional research facilities and office space in the U.S. The lease term will expire on February 27, 2031, unless terminated earlier. The base rent, subject to abatement provisions, is US$199,280 per month. BeOne Medicines Ltd. has provided a guarantee for all payments due under the sublease.”
Read it in the proxyopen_in_new
Luye License Agreement“In December 2022, we entered into an exclusive license agreement with Shandong Luye Pharmaceutical Co., Ltd. (“Luye”) to develop (exclusive of indications for which Luye has submitted the drug marketing authorization application to the China National Medical Products Administration) and commercialize BAITUOWEI®, the world’s first and only approved microsphere formulation of Goserelin, in mainland China. Under the terms of the agreement, BeOne paid Luye an upfront license payment of US$48,665,000, exclusive of VAT, and a prepayment of US$30,000,000 to be applied toward future supply purchases in December 2022. Luye is also eligible to receive future milestone payments upon achievement of certain regulatory milestones, as well as tiered royalties on net sales. Luye may be deemed to be a related party under Item 404 of Reg. S-K due to Hillhouse Investment Management, Ltd. and related entities being a significant shareholder of both BeOne Medicines Ltd. and Luye.”
Read it in the proxyopen_in_new
Shanghai Campus Agreements“In August 2023, our wholly-owned subsidiary, BeOne Medicines (Hong Kong) Co., Limited, formerly BeiGene (Hong Kong) Co., Limited (“BeOne HK”), entered into a subscription and shareholders’ agreement with GaoYue Centurion II Holdings Limited (“Cayman Gaoyue”) whereby BeOne HK and Cayman Gaoyue entered into a joint venture through BeiGene Shanghai, whereby BeOne HK and Cayman Gaoyue may bid together on and acquire certain properties. BeOne HK owns 95% of BeiGene Shanghai while Cayman Gaoyue owns 5%. The Company’s total capital contribution to BeiGene Shanghai amounted to US$57,000,000, while Cayman Gaoyue contributed US$3,000,000. Cayman Gaoyue may be deemed to be a related party under Item 404 of Reg. S-K due to Hillhouse Capital Management, Ltd. and related entities being a significant shareholder of both BeOne and Cayman Gaoyue.”
Read it in the proxyopen_in_new
Certain Relationships and Related-Party Transactions“In December 2025, BeOne HK entered into a share repurchase agreement with Cayman Gaoyue, pursuant to which BeOne HK shall repurchase from Cayman Gaoyue, and Cayman Gaoyue shall sell and transfer to BeOne HK its all shares held in BeiGene Shanghai at the consideration of US$3,253,130.34 (the “Repurchase Transaction”). The Repurchase Transaction has been completed in February 2026, upon which BeiGene Shanghai is wholly owned by us. Cayman Gaoyue may be deemed to be a related party under Item 404 of Reg. S-K due to Hillhouse Capital Management, Ltd. and related entities being a significant shareholder of both BeOne and Cayman Gaoyue.”
Read it in the proxyopen_in_new
Consulting Agreement“Dr. Xiaodong Wang, our Co-Founder, Chair of our Scientific Advisory Board and director, has been providing scientific and strategic advisory services to us since our founding in 2010. We initially entered into a consulting agreement with Dr. Wang for a term of three years in 2018. On February 24, 2021, we entered into a new consulting agreement on substantially the same terms and conditions (the “2021 Consulting Agreement”) for services to be performed during the period starting on January 1, 2021 and ending on December 31, 2023. On December 7, 2023, we entered into a new consulting agreement (the “2023 Consulting Agreement”) with Dr. Wang, effective January 1, 2024 through December 31, 2026 with substantially the same terms as the 2021 Consulting Agreement. On May 27, 2025, we entered into a new consulting agreement (the “2025 Consulting Agreement”) with Dr. Wang. The 2025 Consulting Agreement supersedes the 2023 Consulting Agreement and is effective from May 27, 2025 through May 27, 2028, with substantially the same terms as the 2023 Consulting Agreement.”
Read it in the proxyopen_in_new
Consulting Agreement“In accordance with Dr. Wang’s 2025 Consulting Agreement, he will continue to lead our Scientific Advisory Board and provide short- and long-term strategic advice to our Company in his areas of expertise, participate in our leadership team meetings from time to time, and interact with our key stakeholders on behalf of the Company. Through these and other contributions, Dr. Wang has helped us make significant progress on our research, development and business goals. For example, during 2025, Dr. Wang:”
Read it in the proxyopen_in_new
Consulting Agreement“We believe that Dr. Wang’s international stature in scientific and biotechnology communities provides us with significant intangible benefits and access to key stakeholders in our industry. His scientific expertise and knowledge of oncology research and development are highly valuable to our Company, and his compensation is set to be in line with his major contributions to our Company that go far beyond his responsibilities and time commitment as a non-employee director.”
Read it in the proxyopen_in_new
Consulting Agreement“Under the Consulting Agreement, Dr. Wang is entitled to an annual fixed consulting fee of US$100,000 (subject to review and adjustments by the Board of Directors from time to time) and such additional compensation, which, if any, shall be determined in our sole discretion, subject to compliance with the requirements of the applicable stock exchange listing rules. In recognition of his significant contributions to our Company, in fiscal year 2025, we granted Dr. Wang a cash bonus in the amount of US$150,000 to be paid in 2026, an option to purchase 410,657 ordinary shares that had a grant date fair value of US$2,666,642 and an award of RSUs for 108,992 ordinary shares with a grant”
Read it in the proxyopen_in_new
Certain Relationships and Related-Party Transactions“date fair value of US$1,333,308. As of December 31, 2025, the aggregate number of ordinary shares subject to options and to RSUs held by Dr. Wang was 185,796 and 98,696, respectively. Further, under death or disability termination, all equity awards are accelerated and a pro rata bonus is paid to reflect the portion of the year that Dr. Xiaodong Wang worked.”
Read it in the proxyopen_in_new
Pi Health Agreements“In November 2023, our wholly-owned subsidiary, BeOne Medicines USA, Inc., entered into a master services agreement and subsequently two related statements of work as well as a subscription agreement with Pi Health, in exchange for Pi Health providing (i) implementation services surrounding FICS and a subscription to the FICS platform, and (ii) clinical trial and engineering services. Under these agreements, BeOne agreed to pay Pi Health payments totaling US$52,000,000 distributed over various quarterly and annual payments throughout the subsequent five years. In January 2026, BeOne Medicines USA, Inc. entered into amendments to certain of these agreements, pursuant to which payment schedules were modified.”
Read it in the proxyopen_in_new
Pi Health Agreements“From January 15, 2024, BeOne Medicines USA, Inc. received certain clinical and regulatory services including access to a clinic-regulatory information platform from Pi Health, Ltd. and after the divestiture from Pi Health USA, LLC, a subsidiary of Pi Health, and on September 27, 2024, BeOne Medicines USA, Inc. and Pi Health USA, LLC entered into a subscription and services agreement for an initial term of three years and an annual fee of US$300,000.”
Read it in the proxyopen_in_new
Pi Health Agreements“In January 2026, our wholly-owned subsidiary, BeOne Medicines I GmbH, entered into a preferred stock purchase agreement in connection with Pi Health’s Series Seed funding, pursuant to which BeOne Medicines I GmbH invested $1.8 million in Pi Health and will invest an additional $1.8 million contingent upon Pi Health’s achievement of certain performance milestones. Following the Series Seed funding, BeOne Medicines Ltd. and BeOne Medicines I GmbH collectively hold a minority of the preferred shares and a minority of the total outstanding shares in Pi Health. Mr. John V. Oyler, BeOne’s Co-Founder, Chairman and Chief Executive Officer, holds less than 20% of the total outstanding shares of Pi Health Inc. following the Series Seed funding.”
Read it in the proxyopen_in_new
Services Agreements with Constellation Software“In February 2024, our wholly-owned subsidiary, BeOne Medicines USA, Inc. (“BeOne USA”) entered into a Master Services Agreement (as amended, supplemented or otherwise modified from time to time, “MSA”) with Constellation Software Inc. (“Constellation”). Under the MSA, Constellation agreed to use its data analysis platform and other proprietary technology to provide us with certain advanced data analytics support. In March 2026 and April 2026, BeOne USA entered into order forms with Constellation under the MSA, pursuant to which Constellation agreed to provide data analytics support services in exchange for payments in an aggregate amount of approximately $174,999. The Co-Founder and Chief Executive Officer of Constellation, Diana Lee, is the spouse of Chan Lee, our Senior Vice President, General Counsel and Corporate Secretary.”
Read it in the proxyopen_in_new
No longer reported 4 paragraphs of the proxy filed Apr 7, 2025 with nothing like them this year
Certain Relationships and Related-Party Transactions“Other than compensation arrangements, we describe below any transactions and series of similar transactions, since January 1, 2024 to which we were a party or will be a party, in which:”
Read it in last year's proxyopen_in_new
Certain Relationships and Related-Party Transactions“the amounts involved exceeded or will exceed US$120,000; and any of our directors, executive officers or holders of more than 5% of our share capital, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest.”
Read it in last year's proxyopen_in_new
Certain Relationships and Related-Party Transactions“We have a written related party transactions policy adopted in accordance with the rules of the SEC that requires transactions between us and any director, executive officer, holder of 5% or more of any class of our capital shares or any member of the immediate family of, or entities affiliated with, any of them, or any other related persons (as defined in Item 404 of Regulation S-K) or their affiliates, in which the amount involved is equal to or greater than US$120,000, be approved in advance by our Audit Committee. Any request for such a transaction must first be presented to our Audit Committee for review, consideration and approval. In approving or rejecting any such proposal, our Audit Committee is to consider the relevant facts and circumstances available and deemed relevant to the Audit Committee, including, but not limited to, the extent of the related party’s interest in the transaction, and whether the transaction is on terms no less favorable to us than terms we could have generally obtained from an unaffiliated third party under the same or similar circumstances.”
Read it in last year's proxyopen_in_new
Certain Relationships and Related-Party Transactions“We believe that all of the transactions described below were made on terms no less favorable to us than could have been obtained from unaffiliated third parties. Compensation arrangements for our directors and named executive officers are described in the sections of this Proxy Statement titled “Director Compensation” and “Executive Compensation.””
Read it in last year's proxyopen_in_new
New wording of the review policy 17 paragraphs without an amount or a name
Certain Relationships and Related-Party Transactions“until the latest of the expiration of the last valid patent claim, the expiration of regulatory exclusivity, or the earlier of eight years after the first commercial sale of such product in the country of sale and 20 years from the date of first commercial sale of such product anywhere in the world.”
Read it in the proxyopen_in_new
Certain Relationships and Related-Party Transactions“For each pipeline product that is approved in the Collaboration Territory, we will have the right to commercialize the product for seven years, with the parties sharing profits and losses for the product in the Collaboration Territory equally. After the expiration of the seven-year commercialization period, each product will be transitioned back to Amgen, and we will be eligible to receive tiered mid-single to low-double digit royalties on net sales in the Collaboration Territory for an additional five years. The parties are subject to specified exclusivity requirements in the Collaboration Territory and the rest of the world.”
Read it in the proxyopen_in_new
Certain Relationships and Related-Party Transactions“In connection with our ongoing assessment of the Collaboration Agreement cost-share contributions, we determined that our further investment in the development of LUMAKRAS (sotorasib) (“AMG 510”) was no longer commercially viable for BeOne. As a result, in February 2023, we entered into the Second Amendment to the Collaboration Agreement to (i) stop sharing costs with Amgen for the further development of AMG 510 during the period starting January 1, 2023 and ending August 31, 2023; and (ii) cooperate in good faith to prepare a transition plan with the anticipated termination of AMG 510 from the Collaboration Agreement.”
Read it in the proxyopen_in_new
Certain Relationships and Related-Party Transactions“BeOne Medicines Ltd. has guaranteed certain obligations of BeOne Switzerland under the Collaboration Agreement pursuant to the terms of a separate Guarantee Agreement, and the Collaboration Agreement provides that each party may perform the activities designated to it by itself or through any of its affiliates.”
Read it in the proxyopen_in_new
Certain Relationships and Related-Party Transactions“The Collaboration Agreement contains customary representations, warranties and covenants by the parties. The agreement will continue in effect on a product-by-product basis unless terminated by either party pursuant to its terms. The agreement may be terminated by mutual written consent of the parties, or by either party upon the other party’s uncured material breach, insolvency, failure to comply with specified compliance provisions, or subject to a specified negotiation mechanism, certain adverse economic impacts or the failure to meet commercial objectives. In addition, Amgen may terminate the agreement with respect to a pipeline product in the event that it suspends development of such pipeline product on specified terms, subject to the parties determining whether to continue development of the pipeline product in the Collaboration Territory.”
Read it in the proxyopen_in_new
Share Purchase Agreement“Pursuant to the Share Purchase Agreement, Amgen agreed to (i) a lock-up on sales of its shares of BeOne Medicines Ltd., (ii) a standstill until the date on which it holds less than 5% of our then outstanding shares, and (iii) a voting agreement to vote its shares on certain matters presented for shareholder approval until the later of (a) the fifth anniversary of the closing (January 2, 2025) and (b) the expiration of the standstill period, all under specified circumstances and as set forth in the agreement. Following the later of (i) the expiration of the lock-up period and (ii) the expiration of the standstill period, Amgen has agreed not to sell shares representing more than 5% of our then outstanding shares in any rolling 12-month period. The lock-up has since expired and under the terms of the Share Purchase Agreement, Amgen now has specified registration rights. Additionally, we have agreed to use reasonable best efforts to provide Amgen with an opportunity to participate in subsequent new securities offerings upon the same terms and conditions as other purchasers in the offering, in an amount needed to allow Amgen to hold up to 20.6% of our shares, subject to applicable law and HKEx rules and other specified conditions.”
Read it in the proxyopen_in_new
Share Purchase Agreement“On March 17, 2020, BeOne Medicines Ltd. and Amgen entered into an Amendment No. 2 to the Share Purchase Agreement in order to account for periodic dilution from the issuance of shares by us, which agreement was restated in its entirety on September 24, 2020 (the “Restated Second Amendment”). Pursuant to the Restated Second Amendment, Amgen had an option (the “Direct Purchase Option”) to subscribe for additional ADSs in an amount”
Read it in the proxyopen_in_new
Certain Relationships and Related-Party Transactions“necessary to enable it to increase (and subsequently maintain) its ownership at approximately 20.6% of our outstanding shares. The Direct Purchase Option was exercisable on a monthly basis, but only if Amgen’s interest in our outstanding shares at the monthly reference date was less than 20.4%. The Direct Purchase Option (i) was exercisable by Amgen solely as a result of dilution arising from issuance of new shares by us under our equity incentive plans from time to time, and (ii) was subject to annual approval by our independent shareholders each year during the term of the Restated Second Amendment. The exercise period of the Direct Purchase Option commenced on December 1, 2020 and terminated on December 1, 2023.”
Read it in the proxyopen_in_new
Sublease Agreement“Based solely on a Form 4 filed by Amgen on September 13, 2021, Amgen owns approximately 17.05% of the Company’s outstanding share capital as of April 20, 2026.”
Read it in the proxyopen_in_new
Shanghai Campus Agreements“In July 2023, we entered into a service agreement with Shanghai Gaoyue Management Consulting Co., Ltd. (“Shanghai Gaoyue”) pursuant to which Shanghai Gaoyue, jointly with an independent third-party contractor, Lendlease, agreed to provide certain construction project due diligence and project management services. Under the terms of the agreement, BeOne will pay Shanghai Gaoyue RMB 3,660,000 for such services. On April 10, 2024, the parties entered into an extension agreement, effective as of February 1, 2024, to extend the service term under the service agreement from February 1, 2024 to September 30, 2024, pursuant to which BeOne Medicines Ltd. will”
Read it in the proxyopen_in_new
Certain Relationships and Related-Party Transactions“pay an additional fee of RMB 1,395,940 for the services provided within the extended term. Shanghai Gaoyue may be deemed to be a related party under Item 404 of Reg. S-K due to Hillhouse Capital Management, Ltd. and related entities being a significant shareholder of both BeOne Medicines Ltd. and Shanghai Gaoyue.”
Read it in the proxyopen_in_new
Consulting Agreement“Provided strategic advice to our Chief Executive Officer, President and Chief Operating Officer and President, Global Head of Research and Development, as well as other members of our senior management team in the significant expansion of our global operations, R&D pipeline and commercial portfolio;”
Read it in the proxyopen_in_new
Consulting Agreement“Attended meetings of our research team and provided strategic direction on critical projects that help advance our discovery efforts and new product pipeline;”
Read it in the proxyopen_in_new
Consulting Agreement“Provided strategic direction to assist in the continued development of our commercial-stage manufacturing and clinical R&D campus in Hopewell, New Jersey; and Assisted in the identification and progression of several business development opportunities and engaged in several investor meetings, serving as the Company’s key spokesperson on research and product pipeline.”
Read it in the proxyopen_in_new
Pi Health Agreements“In March 2024, BeOne Medicines Ltd. completed the divestiture of Pi Health, Ltd. and its subsidiaries to Pi Health Inc. (“Pi Health”) in exchange for a majority of the preferred shares in Pi Health and in connection with Pi Health’s Series A funding. Pi Health is a global health technology and clinical research company which has developed front-end interoperable capture software (“FICS”), a digital network that connects life science sponsors and clinical trial sites by automating manual processes for data capture.”
Read it in the proxyopen_in_new
Employment Agreements“For more information regarding employment agreements with our named executive officers, see “Executive Compensation - Employment Agreements with Our Named Executive Officers.””
Read it in the proxyopen_in_new
Indemnification Agreements“Under Swiss law, we may indemnify our directors and officers unless the indemnification results from a breach of their duties that constitutes gross negligence or intentional breach of duty of the director or officer concerned.”
Read it in the proxyopen_in_new
The whole section
As filed
32 paragraphs quoted as filed
Certain Relationships and Related-Party Transactions“until the latest of the expiration of the last valid patent claim, the expiration of regulatory exclusivity, or the earlier of eight years after the first commercial sale of such product in the country of sale and 20 years from the date of first commercial sale of such product anywhere in the world.”
Read it in the proxyopen_in_new
Certain Relationships and Related-Party Transactions“For each pipeline product that is approved in the Collaboration Territory, we will have the right to commercialize the product for seven years, with the parties sharing profits and losses for the product in the Collaboration Territory equally. After the expiration of the seven-year commercialization period, each product will be transitioned back to Amgen, and we will be eligible to receive tiered mid-single to low-double digit royalties on net sales in the Collaboration Territory for an additional five years. The parties are subject to specified exclusivity requirements in the Collaboration Territory and the rest of the world.”
Read it in the proxyopen_in_new
Certain Relationships and Related-Party Transactions“In connection with our ongoing assessment of the Collaboration Agreement cost-share contributions, we determined that our further investment in the development of LUMAKRAS (sotorasib) (“AMG 510”) was no longer commercially viable for BeOne. As a result, in February 2023, we entered into the Second Amendment to the Collaboration Agreement to (i) stop sharing costs with Amgen for the further development of AMG 510 during the period starting January 1, 2023 and ending August 31, 2023; and (ii) cooperate in good faith to prepare a transition plan with the anticipated termination of AMG 510 from the Collaboration Agreement.”
Read it in the proxyopen_in_new
Certain Relationships and Related-Party Transactions“BeOne Medicines Ltd. has guaranteed certain obligations of BeOne Switzerland under the Collaboration Agreement pursuant to the terms of a separate Guarantee Agreement, and the Collaboration Agreement provides that each party may perform the activities designated to it by itself or through any of its affiliates.”
Read it in the proxyopen_in_new
Certain Relationships and Related-Party Transactions“The Collaboration Agreement contains customary representations, warranties and covenants by the parties. The agreement will continue in effect on a product-by-product basis unless terminated by either party pursuant to its terms. The agreement may be terminated by mutual written consent of the parties, or by either party upon the other party’s uncured material breach, insolvency, failure to comply with specified compliance provisions, or subject to a specified negotiation mechanism, certain adverse economic impacts or the failure to meet commercial objectives. In addition, Amgen may terminate the agreement with respect to a pipeline product in the event that it suspends development of such pipeline product on specified terms, subject to the parties determining whether to continue development of the pipeline product in the Collaboration Territory.”
Read it in the proxyopen_in_new
Share Purchase Agreement“In connection with the Collaboration Agreement, pursuant to a Share Purchase Agreement dated October 31, 2019, by and between the Company and Amgen (as amended, the “Share Purchase Agreement”), we issued 206,635,013 ordinary shares in the form of 15,895,001 ADSs on January 2, 2020, representing approximately 20.5% of our then outstanding shares to Amgen, for an aggregate purchase price of US$2.78 billion, or US$13.45 per ordinary share, or US$174.85 per ADS.”
Read it in the proxyopen_in_new
Share Purchase Agreement“Pursuant to the Share Purchase Agreement, Amgen agreed to (i) a lock-up on sales of its shares of BeOne Medicines Ltd., (ii) a standstill until the date on which it holds less than 5% of our then outstanding shares, and (iii) a voting agreement to vote its shares on certain matters presented for shareholder approval until the later of (a) the fifth anniversary of the closing (January 2, 2025) and (b) the expiration of the standstill period, all under specified circumstances and as set forth in the agreement. Following the later of (i) the expiration of the lock-up period and (ii) the expiration of the standstill period, Amgen has agreed not to sell shares representing more than 5% of our then outstanding shares in any rolling 12-month period. The lock-up has since expired and under the terms of the Share Purchase Agreement, Amgen now has specified registration rights. Additionally, we have agreed to use reasonable best efforts to provide Amgen with an opportunity to participate in subsequent new securities offerings upon the same terms and conditions as other purchasers in the offering, in an amount needed to allow Amgen to hold up to 20.6% of our shares, subject to applicable law and HKEx rules and other specified conditions.”
Read it in the proxyopen_in_new
Share Purchase Agreement“On March 17, 2020, BeOne Medicines Ltd. and Amgen entered into an Amendment No. 2 to the Share Purchase Agreement in order to account for periodic dilution from the issuance of shares by us, which agreement was restated in its entirety on September 24, 2020 (the “Restated Second Amendment”). Pursuant to the Restated Second Amendment, Amgen had an option (the “Direct Purchase Option”) to subscribe for additional ADSs in an amount”
Read it in the proxyopen_in_new
Certain Relationships and Related-Party Transactions“necessary to enable it to increase (and subsequently maintain) its ownership at approximately 20.6% of our outstanding shares. The Direct Purchase Option was exercisable on a monthly basis, but only if Amgen’s interest in our outstanding shares at the monthly reference date was less than 20.4%. The Direct Purchase Option (i) was exercisable by Amgen solely as a result of dilution arising from issuance of new shares by us under our equity incentive plans from time to time, and (ii) was subject to annual approval by our independent shareholders each year during the term of the Restated Second Amendment. The exercise period of the Direct Purchase Option commenced on December 1, 2020 and terminated on December 1, 2023.”
Read it in the proxyopen_in_new
Certain Relationships and Related-Party Transactions“On January 30, 2023, BeOne Medicines Ltd. and Amgen entered into an Amendment No. 3 to the Share Purchase Agreement, pursuant to which Amgen elected to relinquish its right to appoint a designated director to the Company’s Board of Directors on account of the Company’s global growth. Mr. Anthony C. Hooper, who was Amgen’s director designee, was most recently re-elected by shareholders in 2025.”
Read it in the proxyopen_in_new
Sublease Agreement“On January 17, 2025, our wholly-owned subsidiary, BeOne Medicines US Holdings, LLC entered into a sublease agreement with ChemoCentryx, Inc., an affiliate of Amgen, to lease property in San Carlos, California, for the establishment of additional research facilities and office space in the U.S. The lease term will expire on February 27, 2031, unless terminated earlier. The base rent, subject to abatement provisions, is US$199,280 per month. BeOne Medicines Ltd. has provided a guarantee for all payments due under the sublease.”
Read it in the proxyopen_in_new
Sublease Agreement“Based solely on a Form 4 filed by Amgen on September 13, 2021, Amgen owns approximately 17.05% of the Company’s outstanding share capital as of April 20, 2026.”
Read it in the proxyopen_in_new
Luye License Agreement“In December 2022, we entered into an exclusive license agreement with Shandong Luye Pharmaceutical Co., Ltd. (“Luye”) to develop (exclusive of indications for which Luye has submitted the drug marketing authorization application to the China National Medical Products Administration) and commercialize BAITUOWEI®, the world’s first and only approved microsphere formulation of Goserelin, in mainland China. Under the terms of the agreement, BeOne paid Luye an upfront license payment of US$48,665,000, exclusive of VAT, and a prepayment of US$30,000,000 to be applied toward future supply purchases in December 2022. Luye is also eligible to receive future milestone payments upon achievement of certain regulatory milestones, as well as tiered royalties on net sales. Luye may be deemed to be a related party under Item 404 of Reg. S-K due to Hillhouse Investment Management, Ltd. and related entities being a significant shareholder of both BeOne Medicines Ltd. and Luye.”
Read it in the proxyopen_in_new
Shanghai Campus Agreements“In August 2023, our wholly-owned subsidiary, BeOne Medicines (Hong Kong) Co., Limited, formerly BeiGene (Hong Kong) Co., Limited (“BeOne HK”), entered into a subscription and shareholders’ agreement with GaoYue Centurion II Holdings Limited (“Cayman Gaoyue”) whereby BeOne HK and Cayman Gaoyue entered into a joint venture through BeiGene Shanghai, whereby BeOne HK and Cayman Gaoyue may bid together on and acquire certain properties. BeOne HK owns 95% of BeiGene Shanghai while Cayman Gaoyue owns 5%. The Company’s total capital contribution to BeiGene Shanghai amounted to US$57,000,000, while Cayman Gaoyue contributed US$3,000,000. Cayman Gaoyue may be deemed to be a related party under Item 404 of Reg. S-K due to Hillhouse Capital Management, Ltd. and related entities being a significant shareholder of both BeOne and Cayman Gaoyue.”
Read it in the proxyopen_in_new
Shanghai Campus Agreements“In July 2023, we entered into a service agreement with Shanghai Gaoyue Management Consulting Co., Ltd. (“Shanghai Gaoyue”) pursuant to which Shanghai Gaoyue, jointly with an independent third-party contractor, Lendlease, agreed to provide certain construction project due diligence and project management services. Under the terms of the agreement, BeOne will pay Shanghai Gaoyue RMB 3,660,000 for such services. On April 10, 2024, the parties entered into an extension agreement, effective as of February 1, 2024, to extend the service term under the service agreement from February 1, 2024 to September 30, 2024, pursuant to which BeOne Medicines Ltd. will”
Read it in the proxyopen_in_new
Certain Relationships and Related-Party Transactions“pay an additional fee of RMB 1,395,940 for the services provided within the extended term. Shanghai Gaoyue may be deemed to be a related party under Item 404 of Reg. S-K due to Hillhouse Capital Management, Ltd. and related entities being a significant shareholder of both BeOne Medicines Ltd. and Shanghai Gaoyue.”
Read it in the proxyopen_in_new
Certain Relationships and Related-Party Transactions“In December 2025, BeOne HK entered into a share repurchase agreement with Cayman Gaoyue, pursuant to which BeOne HK shall repurchase from Cayman Gaoyue, and Cayman Gaoyue shall sell and transfer to BeOne HK its all shares held in BeiGene Shanghai at the consideration of US$3,253,130.34 (the “Repurchase Transaction”). The Repurchase Transaction has been completed in February 2026, upon which BeiGene Shanghai is wholly owned by us. Cayman Gaoyue may be deemed to be a related party under Item 404 of Reg. S-K due to Hillhouse Capital Management, Ltd. and related entities being a significant shareholder of both BeOne and Cayman Gaoyue.”
Read it in the proxyopen_in_new
Consulting Agreement“Dr. Xiaodong Wang, our Co-Founder, Chair of our Scientific Advisory Board and director, has been providing scientific and strategic advisory services to us since our founding in 2010. We initially entered into a consulting agreement with Dr. Wang for a term of three years in 2018. On February 24, 2021, we entered into a new consulting agreement on substantially the same terms and conditions (the “2021 Consulting Agreement”) for services to be performed during the period starting on January 1, 2021 and ending on December 31, 2023. On December 7, 2023, we entered into a new consulting agreement (the “2023 Consulting Agreement”) with Dr. Wang, effective January 1, 2024 through December 31, 2026 with substantially the same terms as the 2021 Consulting Agreement. On May 27, 2025, we entered into a new consulting agreement (the “2025 Consulting Agreement”) with Dr. Wang. The 2025 Consulting Agreement supersedes the 2023 Consulting Agreement and is effective from May 27, 2025 through May 27, 2028, with substantially the same terms as the 2023 Consulting Agreement.”
Read it in the proxyopen_in_new
Consulting Agreement“In accordance with Dr. Wang’s 2025 Consulting Agreement, he will continue to lead our Scientific Advisory Board and provide short- and long-term strategic advice to our Company in his areas of expertise, participate in our leadership team meetings from time to time, and interact with our key stakeholders on behalf of the Company. Through these and other contributions, Dr. Wang has helped us make significant progress on our research, development and business goals. For example, during 2025, Dr. Wang:”
Read it in the proxyopen_in_new
Consulting Agreement“Provided strategic advice to our Chief Executive Officer, President and Chief Operating Officer and President, Global Head of Research and Development, as well as other members of our senior management team in the significant expansion of our global operations, R&D pipeline and commercial portfolio;”
Read it in the proxyopen_in_new
Consulting Agreement“Attended meetings of our research team and provided strategic direction on critical projects that help advance our discovery efforts and new product pipeline;”
Read it in the proxyopen_in_new
Consulting Agreement“Provided strategic direction to assist in the continued development of our commercial-stage manufacturing and clinical R&D campus in Hopewell, New Jersey; and Assisted in the identification and progression of several business development opportunities and engaged in several investor meetings, serving as the Company’s key spokesperson on research and product pipeline.”
Read it in the proxyopen_in_new
Consulting Agreement“We believe that Dr. Wang’s international stature in scientific and biotechnology communities provides us with significant intangible benefits and access to key stakeholders in our industry. His scientific expertise and knowledge of oncology research and development are highly valuable to our Company, and his compensation is set to be in line with his major contributions to our Company that go far beyond his responsibilities and time commitment as a non-employee director.”
Read it in the proxyopen_in_new
Consulting Agreement“Under the Consulting Agreement, Dr. Wang is entitled to an annual fixed consulting fee of US$100,000 (subject to review and adjustments by the Board of Directors from time to time) and such additional compensation, which, if any, shall be determined in our sole discretion, subject to compliance with the requirements of the applicable stock exchange listing rules. In recognition of his significant contributions to our Company, in fiscal year 2025, we granted Dr. Wang a cash bonus in the amount of US$150,000 to be paid in 2026, an option to purchase 410,657 ordinary shares that had a grant date fair value of US$2,666,642 and an award of RSUs for 108,992 ordinary shares with a grant”
Read it in the proxyopen_in_new
Certain Relationships and Related-Party Transactions“date fair value of US$1,333,308. As of December 31, 2025, the aggregate number of ordinary shares subject to options and to RSUs held by Dr. Wang was 185,796 and 98,696, respectively. Further, under death or disability termination, all equity awards are accelerated and a pro rata bonus is paid to reflect the portion of the year that Dr. Xiaodong Wang worked.”
Read it in the proxyopen_in_new
Pi Health Agreements“In March 2024, BeOne Medicines Ltd. completed the divestiture of Pi Health, Ltd. and its subsidiaries to Pi Health Inc. (“Pi Health”) in exchange for a majority of the preferred shares in Pi Health and in connection with Pi Health’s Series A funding. Pi Health is a global health technology and clinical research company which has developed front-end interoperable capture software (“FICS”), a digital network that connects life science sponsors and clinical trial sites by automating manual processes for data capture.”
Read it in the proxyopen_in_new
Pi Health Agreements“In November 2023, our wholly-owned subsidiary, BeOne Medicines USA, Inc., entered into a master services agreement and subsequently two related statements of work as well as a subscription agreement with Pi Health, in exchange for Pi Health providing (i) implementation services surrounding FICS and a subscription to the FICS platform, and (ii) clinical trial and engineering services. Under these agreements, BeOne agreed to pay Pi Health payments totaling US$52,000,000 distributed over various quarterly and annual payments throughout the subsequent five years. In January 2026, BeOne Medicines USA, Inc. entered into amendments to certain of these agreements, pursuant to which payment schedules were modified.”
Read it in the proxyopen_in_new
Pi Health Agreements“From January 15, 2024, BeOne Medicines USA, Inc. received certain clinical and regulatory services including access to a clinic-regulatory information platform from Pi Health, Ltd. and after the divestiture from Pi Health USA, LLC, a subsidiary of Pi Health, and on September 27, 2024, BeOne Medicines USA, Inc. and Pi Health USA, LLC entered into a subscription and services agreement for an initial term of three years and an annual fee of US$300,000.”
Read it in the proxyopen_in_new
Pi Health Agreements“In January 2026, our wholly-owned subsidiary, BeOne Medicines I GmbH, entered into a preferred stock purchase agreement in connection with Pi Health’s Series Seed funding, pursuant to which BeOne Medicines I GmbH invested $1.8 million in Pi Health and will invest an additional $1.8 million contingent upon Pi Health’s achievement of certain performance milestones. Following the Series Seed funding, BeOne Medicines Ltd. and BeOne Medicines I GmbH collectively hold a minority of the preferred shares and a minority of the total outstanding shares in Pi Health. Mr. John V. Oyler, BeOne’s Co-Founder, Chairman and Chief Executive Officer, holds less than 20% of the total outstanding shares of Pi Health Inc. following the Series Seed funding.”
Read it in the proxyopen_in_new
Services Agreements with Constellation Software“In February 2024, our wholly-owned subsidiary, BeOne Medicines USA, Inc. (“BeOne USA”) entered into a Master Services Agreement (as amended, supplemented or otherwise modified from time to time, “MSA”) with Constellation Software Inc. (“Constellation”). Under the MSA, Constellation agreed to use its data analysis platform and other proprietary technology to provide us with certain advanced data analytics support. In March 2026 and April 2026, BeOne USA entered into order forms with Constellation under the MSA, pursuant to which Constellation agreed to provide data analytics support services in exchange for payments in an aggregate amount of approximately $174,999. The Co-Founder and Chief Executive Officer of Constellation, Diana Lee, is the spouse of Chan Lee, our Senior Vice President, General Counsel and Corporate Secretary.”
Read it in the proxyopen_in_new
Employment Agreements“For more information regarding employment agreements with our named executive officers, see “Executive Compensation - Employment Agreements with Our Named Executive Officers.””
Read it in the proxyopen_in_new
Indemnification Agreements“Under Swiss law, we may indemnify our directors and officers unless the indemnification results from a breach of their duties that constitutes gross negligence or intentional breach of duty of the director or officer concerned.”
Read it in the proxyopen_in_new
Paragraphs are compared by their words, not read by AI: one counts as new when no paragraph last year shares half of its words, or when it names a person or company last year's section did not. A deal reported again with a new amount is not new. Always check the filing. Open the proxy ↗ · Last year's proxy ↗
Sources
The related-party section (Item 404) of the latest annual proxy statement (DEF 14A), against last year's, compared by their words.
Also
CEO pay: the same proxy's pay versus performance table.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ONC/export.csv") into a cell.